IO Biotech Valuation
| IOBT Stock | USD 0.35 0.03 9.37% |
IO Biotech seems to be undervalued based on Macroaxis valuation methodology. Our model calculates the value of IO Biotech from inspecting the firm fundamentals such as Return On Asset of -0.89, gross profit of (2.59 M), and Shares Outstanding of 71.95 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting IO Biotech's valuation include:
Undervalued
Today
Please note that IO Biotech's price fluctuation is out of control at this time. Calculation of the real value of IO Biotech is based on 3 months time horizon. Increasing IO Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
IO Biotech's intrinsic value may or may not be the same as its current market price of 0.35, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.35 | Real 0.8 | Target 2.18 | Hype 0.35 | Naive 0.38 |
The intrinsic value of IO Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence IO Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of IO Biotech helps investors to forecast how IOBT stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of IO Biotech more accurately as focusing exclusively on IO Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use IO Biotech's intrinsic value based on its ongoing forecasts of IO Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against IO Biotech's closest peers.
IO Biotech Cash |
|
IO Biotech Total Value Analysis
IO Biotech is currently forecasted to have valuation of 7.54 M with market capitalization of 23.05 M, debt of 1.92 M, and cash on hands of 170.12 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the IO Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.54 M | 23.05 M | 1.92 M | 170.12 M |
IO Biotech Asset Utilization
One of the ways to look at asset utilization of IOBT is to check how much profit was generated for every dollar of assets it reports. IO Biotech owns a negative utilization of current and long term assets of -0.89 %, losing $0.008858 for each dollar of current and long term assets held by the firm. Discouraging asset utilization attests that the company is being less competent with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of IO Biotech shows how wasteful it operates for each dollar spent on its current and long term assets.IO Biotech Profitability Analysis
Considering the key profitability indicators obtained from IO Biotech's historical financial statements, IO Biotech may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess IO Biotech's ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -26.2 M | Current Value -8.4 M | Quarterly Volatility 10 M |
For IO Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of IO Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well IO Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between IO Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of IO Biotech over time as well as its relative position and ranking within its peers.
IO Biotech Earnings per Share Projection vs Actual
By analyzing IO Biotech's earnings estimates, investors can diagnose different trends across IO Biotech's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for IO Biotech is based on EPS before non-recurring items and includes expenses related to employee stock options.IO Biotech Ownership Allocation
IO Biotech secures a total of 71.95 Million outstanding shares. 30% of IO Biotech outstanding shares are owned by institutions. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Hence, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.IO Biotech Profitability Analysis
Net Loss for the year was (95.49 M) with loss before overhead, payroll, taxes, and interest of (2.59 M).About IO Biotech Valuation
The stock valuation mechanism determines IO Biotech's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of IO Biotech based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of IO Biotech. We calculate exposure to IO Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of IO Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -764.1 K | -802.3 K |
IO Biotech Current Valuation Indicators
IO Biotech's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final IO Biotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as IO Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use IO Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes IO Biotech's worth.Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.